We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Court Ruling Allows Amarin to Promote Off-Label Use of Vascepa
Court Ruling Allows Amarin to Promote Off-Label Use of Vascepa
Amarin Pharmaceuticals has a constitutional right to promote its cholesterol-lowering drug Vascepa for an off-label use as long as the communication is truthful and not misleading, a New York federal judge ruled Friday — dealing a blow to FDA efforts to prevent off-label drug promotion.